Did Viemed Healthcare beat or miss consensus estimates last quarter?

What is Viemed Healthcare's gross profit margin?

What is the market's earnings forecast for Viemed Healthcare next quarter?

What does Viemed Healthcare do and what are its main business segments?

What were the key takeaways from Viemed Healthcare’s earnings call?

What is the revenue and EPS growth rate for Viemed Healthcare year over year?

What factors drove the changes in Viemed Healthcare's revenue and profit?

What were the key takeaways from Viemed Healthcare's earnings call?

- **Revenue Growth**: 21% YoY to $270.3M, with sleep therapy up 62% and maternal health contributing $9M.
- **Free Cash Flow**: Doubled to $28.1M, enabling $5M share buyback program.
- **2026 Outlook**: $310-320M revenue (+17%), stable margins, and maternal health as fastest-growing segment.
- **Risk Management**: NCD transition affecting ventilator growth, but 100% Medicare appeal success rate.
- **Strategic Moves**: Technology investment, disciplined workforce expansion, and accretive M&A focus.

**【CEO Summary Section】**
- **Record Performance**: 2025 revenue reached $270.3M (+21% YoY), with adjusted EBITDA of $61.4M (+22.7% margin). Free cash flow doubled to $28.1M.
- **Diversified Growth Engines**: 
  - **Sleep Therapy**: PAP patients grew 62% YoY to 34,528, resupply revenue up 49%.
  - **Maternal Health**: Lehan acquisition added $9M in 2025, with 2026 expansion plans.
  - **Ventilators**: Q4 moderation due to NCD transition, but 100% success rate in Medicare Advantage appeals.
- **Platform Strength**: National payer network, clinical technology (Engage platform), and disciplined workforce expansion (1,382 employees).

**【CFO Financial Commentary】**
- **Q4 2025 Results**: 
  - Revenue: $76.2M (+26% YoY)
  - Adjusted EBITDA: $18.2M
  - Free Cash Flow: $10.8M
- **2026 Guidance**: 
  - Revenue: $310-320M (+17% YoY)
  - EBITDA: $65-69M
  - Free Cash Flow: Expected to grow with >$28M in 2025.
- **Capital Allocation**: Share buyback program announced, with focus on organic growth and accretive M&A.
- **Margins**: Gross margin ~58%, stable EBITDA margin, operating leverage in SG&A.

**【Q&A Highlights】**
- **Maternal Health Expansion**: 
  - Priority: Payer network expansion and cross-trained salesforce.
  - Growth Driver: Projected fastest-growing product line, 2026 onboarding of breast pump salesforce.
- **Margin Stability**: 
  - Levers: Technology efficiency, G&A scalability, and gross margin discipline.
  - Risk: Ventilator growth constrained by NCD, but 2026 Q2+ expected normalization.
- **RT Capacity**: Driven by patient volume, stable with 2026 vent growth potential.


Viemed Healthcare, Inc. (VMD) Q4 2025 Earnings Call Transcript

- **Record Revenue Growth**: Q3 revenue of $71.9 million (24% YoY) driven by sleep therapy (99% YoY new patient starts) and maternity health expansion.
- **AI-Driven Efficiency**: Deployment of AI tools in sleep therapy reduced patient setup time, improving compliance and scalability.
- **Strong Financial Health**: 22.4% EBITDA margin, $23.3 million trailing free cash flow, and $11.1 million cash on hand.
- **Strategic Expansion**: Maternity services launched nationwide in 2026, with rural market focus for ventilation and sleep therapy.
- **Shareholder Value**: Completed 2 million share buyback program, positioning for future capital returns.

**【CEO Summary Section】**
- **Revenue Growth and Diversification**: Q3 revenue reached $71.9 million (24% YoY growth), with ventilation accounting for less than 50% of net revenue for the first time in over a decade. Sleep therapy revenue grew 99% YoY in new patient starts, and maternity health services were launched through the Lehan's acquisition.
- **Operational Expansion**: Employee count increased to 1,386, including 2,465 new hires from Lehan's, enabling seamless integration and market expansion.
- **Strategic Initiatives**: AI-powered revenue cycle management tools were deployed in sleep therapy, improving efficiency and scalability. A share repurchase program was completed, repurchasing 2 million shares at an average price of $6.69.
- **Regulatory Wins**: Medicare Advantage coverage improvements streamlined approvals, positioning the company to capitalize on new national coverage determinations.

**【CFO Financial Commentary】**
- **Financial Performance**: Gross margin of 57.5%, adjusted EBITDA of $16.1 million (22.4% margin), and net income of $3.5 million. SG&A expenses improved by 160 basis points YoY to 44.4% of revenue.
- **Cash Flow and Capital Allocation**: Trailing 12-month free cash flow of $23.3 million, with $11.1 million in cash and $38 million available on credit facilities. Debt was reduced by $5 million in Q3.
- **Guidance Update**: Full-year revenue expected between $271 million and $273 million, with adjusted EBITDA between $60 million and $62 million, reflecting stronger sleep growth and slower-than-expected staffing expansion.

**【Q&A Key Highlights】**
- **Sleep Therapy Growth**: 99% YoY increase in new sleep patient starts driven by targeted sales reps and AI-driven intake processes. Resupply patients now exceed PAP therapy rentals, signaling recurring revenue stability.
- **Competitive Bidding and Payer Mix**: Anticipation of competitive bidding program return, with larger, operationally sound companies likely to win. Payer mix shifted to 6% maternity (non-Medicare) and 30% commercial, reducing Medicare exposure.
- **Technology and Expansion**: AI tools for revenue cycle management are being extended to other service lines. Geographic focus remains on rural markets with high COPD prevalence, while maternity services will expand nationwide in 2026.
- **Shareholder Returns**: Buyback program completed in Q3, with plans to evaluate further capital returns based on stock performance and debt repayment progress.

Viemed Healthcare, Inc. (VMD) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: 14.7% YoY growth driven by core ventilation (11% YoY) and rapid expansion of sleep therapy (+51% YoY patients).
- **Strategic Expansion**: $27 million annualized revenue from Lehan's acquisition, entering maternal health and enhancing Midwest market share.
- **Operational Efficiency**: 250 basis point SG&A improvement to 45.7% of revenue, supporting 12% YoY EBITDA growth.
- **Regulatory Win**: NCD rule elimination of BiPAP step therapy reduces patient barriers, positioning Viemed for industry consolidation.
- **Guidance Uptick**: Full-year 2025 revenue raised to $271-$277 million (22% YoY growth), EBITDA to $59-$62 million (18% YoY growth).

**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue increased 14.7% year-over-year, driven by organic growth across core and complementary businesses.
- **Core Ventilation Business**: Active ventilator patient count grew for the 17th consecutive quarter, with vent revenue up 11% YoY.
- **Sleep Therapy Expansion**: Sleep therapy patients rose 51% YoY, with new setups up 72% YoY, supported by 8 new sleep areas launched this year.
- **Resupply Growth**: Resupply revenue increased 25% YoY, benefiting from patient maturation and competitor transfers.
- **Strategic Acquisition**: Acquisition of Lehan's Medical Equipment expanded into maternal health, adding $27 million in annualized revenue and enhancing Illinois/Wisconsin market penetration.
- **Regulatory Impact**: NCD final rule eliminated step therapy for BiPAP, reducing operational burden and positioning Viemed for industry consolidation opportunities.

**【CFO Financial Commentary】**
- **Gross Margin**: 58.3% for Q2, down 1.5% YoY due to diversification into lower-margin businesses like sleep and staffing.
- **Adjusted EBITDA**: $14.3 million (12% YoY growth), with margin at 22.7%, aligning with full-year projections.
- **Cost Efficiency**: SG&A improved 250 basis points YoY to 45.7% of revenue, driven by operational leverage.
- **Liquidity**: $55 million available on credit facilities, $20 million cash on hand, and no net debt.
- **Share Repurchases**: $1.8 million spent on 5% share buyback program in Q2, with additional purchases in Q3.
- **Updated Guidance**: Full-year 2025 net revenue raised to $271-$277 million (22% YoY growth), EBITDA to $59-$62 million (18% YoY growth).

**【Q&A Highlights】**
- **Ventilator Exchange Program**: Philips repurchased outdated vents, providing cash above net book value and newer, technologically advanced equipment.
- **Sleep Growth Drivers**: Increased focus on sleep salesforce, GLP-1 medication adoption boosting sleep health awareness, and maturing PAP therapy patients entering resupply.
- **Staffing Slowdown**: Sequential decline due to state appropriations delays, but 76% of business now focused on behavioral health, with normalized growth expected.
- **Competitive Bidding Outlook**: CMS may reintroduce DME competitive bidding by 2027, with Viemed well-positioned to leverage scale and operational efficiency.

Viemed Healthcare (VMD)-7 Aug 25-2025 Q2 Earnings call transcript

- **Q1 Growth Surpasses Expectations**: 16.9% total revenue growth, 26% EBITDA increase, and 14.5% organic expansion.
- **Strong Business Momentum**: Vent patients up 10% YoY, sleep setups +40% YoY, and staffing business at 10% of revenue.
- **Strategic Expansion**: $26M Lehan's acquisition to unlock Chicago market and women's health, with potential $7.4M annual EBITDA.
- **Regulatory Tailwind**: State laws reducing step therapy barriers align with CMS NCD progress.
- **Financial Strength**: No net debt, $55M credit capacity, and 21.6% EBITDA margin.

**【CEO Summary Section】**
- **Revenue Growth**: Organic revenue increased 14.5% year-over-year, with total revenue up 16.9% to $254-$265 million. 
- **Business Performance**: 
  - Vent business (54% of revenue) saw 10% YoY growth, with new patient starts up 9% sequentially.
  - Sleep business (16% of revenue) achieved 46% YoY patient growth and 40% YoY new setups.
  - Staffing business (10% of revenue) expanded due to demand in behavioral health.
- **Strategic Acquisition**: $26 million purchase of Lehan's Medical Equipment to expand into Chicago market and women's health, with potential $7.4 million annual EBITDA contribution.
- **Regulatory Progress**: CMS NCD on NIV shows alignment with company data; Arkansas, Louisiana, and Oklahoma passed laws reducing step therapy barriers.

**【COO Financial Commentary】**
- **Profitability**: Adjusted EBITDA rose 26% to $12.8 million (21.6% margin), driven by cost control (SG&A down 90bps YoY to 48% of revenue).
- **CapEx Management**: Net CapEx of $8.5 million (14.4% of revenue) due to Philips ventilator exchange program; expects normalization post-Q2.
- **Balance Sheet**: $55 million available on credit facilities, $10.2 million cash on hand, and no net debt.

**【Q&A Highlights】**
- **Sales Restructuring Success**: 16 straight quarters of vent patient growth, 9% sequential new starts, and 40% YoY sleep setups.
- **Chicago Market Expansion**: Lehan's 90+ employees and 6 locations provide beachhead for respiratory care expansion.
- **VA Opportunity**: CEO declared VA pursuit 'dead' due to systemic issues, though open to revisiting if reforms occur.
- **Acquisition Synergies**: Lehan's 70% transactional business (vs. Viemed's 54%) offers higher margin opportunities through resupply and maternal health products.

Actual			0.11	0.48	0.07	0.12	0.04	0.04	0.04	0.1	0.04	0.02	0.03	0.06	0.04	0.06	0.07	0.09	0.04	0.04	0.1	0.1	0.06	0.08	0.09	0.14
Forecast			0.08	0.2232	0.0767	0.0533	0.0433	0.03	0.0425	0.06	0.0567	0.055	0.04	0.05	0.0467	0.055	0.095	0.105	0.07	0.07	0.075	0.105	0.06	0.085	0.09	0.125
Surprise	0.00%	0.00%	+37.50%	+115.05%	-8.74%	+125.14%	-7.62%	+33.33%	-5.88%	+66.67%	-29.45%	-63.64%	-25.00%	+20.00%	-14.35%	+9.09%	-26.32%	-14.29%	-42.86%	-42.86%	+33.33%	-4.76%	0.00%	-5.88%	0.00%	+12.00%

VMD

VMD fundamentals

VMD Q4 2025 Earnings

Earnings Call

You can ask Aime

VMD

VMD fundamentals

VMD Q4 2025 Earnings

Earnings Call

VMD Earnings Call Summary for Q4/202511:00 AM on Mar 5, 2026

VMD Earnings Call Summary for Q3/202511:00 AM on Nov 6, 2025

VMD Earnings Call Summary for Q2/202511:00 AM on Aug 7, 2025

VMD Earnings Call Summary for Q1/202511:00 AM on May 8, 2025

VMD Earnings Call Summary for Q4/2024 Apr 1, 2026

You can ask Aime